Lisa Mueller
Michael Best & Friedrich LLP, USA
Title: Biosimilar Companies and Market Development Worldwide
Biography
Biography: Lisa Mueller
Abstract
Biosimilars are highly-similar versions of biological drugs (biologics) approved for the treatment of a variety of disorders and diseases. Originator biologics are the most expensive drugs in the pharmaceutical industry and many cost nearly $100,000 per patient per year. As a result, biologics impose a heavy financial burden on patients and healthcare systems. While patent protection for several biologics has already expired, several other biologics are expected to lose patent protection between now and 2020. This impending patent cliff has given many biotechnology companies the opportunity to develop and market biosimilars with a cost benefit of about 20% to 30%. In order to gain a slice of the $190 billion worth of biologic’s market, many biotechnology companies have ventured into the biosimilar sector. This session will examine the key players that have ventured into this sector as well as the size and development of the market worldwide.
